Press Releases

Date Title
Toggle Summary Kura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference
SAN DIEGO , May 03, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Deutsche Bank 43rd Annual Health Care Conference .
Toggle Summary Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
– Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 – – Second U.S. patent for tipifarnib reinforces potential for broader strategy to provide commercial exclusivity based upon biomarker-guided development – –
Toggle Summary Kura Oncology to Report First Quarter 2018 Financial Results
SAN DIEGO , May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2018 financial results after the close of U.S.
Toggle Summary Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
SAN DIEGO , April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that three abstracts relating to the company’s lead product candidate, tipifarnib, and ERK
Toggle Summary Kura Oncology to Present at Oppenheimer 28th Annual Healthcare Conference
SAN DIEGO , March 16, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Oppenheimer 28th Annual Healthcare Conference.
Toggle Summary Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results
– Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 following recent end of Phase 2 meeting with the FDA – – Single-arm trial to enroll at least 59 recurrent or metastatic HRAS mutant HNSCC patients with response rate as primary endpoint – – Company expects
Toggle Summary Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference
SAN DIEGO , March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Cowen and Company 38th Annual Health Care Conference .
Toggle Summary Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2017 financial results after the close of
Toggle Summary Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – – Initiation of registrational trial in HRAS mutant HNSCC anticipated this year – SAN DIEGO , Feb.
Toggle Summary Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Leerink Partners 7th Annual Global Healthcare Conference.